9月16日,在奥地利维也纳举行的第61届欧洲糖尿病研究协会(EASD)年会上,北京大学人民医院纪立农教授报告——HTD1801在2型糖尿病(T2DM)Ⅲ期临床研究中达到主要疗效终点,并观察到心肾代谢多重疗效获益数据。SYMPHONY 2(NCT06353347)试验是一项随机、双盲、安慰剂对照的临床Ⅲ期试验,在61家中国临床试验机构开展,旨在评估HTD1801在二甲双胍治疗后血糖控制不佳的T2DM...
Source Link9月16日,在奥地利维也纳举行的第61届欧洲糖尿病研究协会(EASD)年会上,北京大学人民医院纪立农教授报告——HTD1801在2型糖尿病(T2DM)Ⅲ期临床研究中达到主要疗效终点,并观察到心肾代谢多重疗效获益数据。SYMPHONY 2(NCT06353347)试验是一项随机、双盲、安慰剂对照的临床Ⅲ期试验,在61家中国临床试验机构开展,旨在评估HTD1801在二甲双胍治疗后血糖控制不佳的T2DM...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.